Dr. Reddy's gets India approval for Zytorvi in advanced esophageal cancer
RDY•Dr. Reddy's received Indian regulatory approval for Zytorvi as a first-line treatment for adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma, in combination with cisplatin and paclitaxel.
1. India approval
Dr. Reddy's received Indian regulatory approval for Zytorvi as a first-line treatment for adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma. The treatment combines Zytorvi with cisplatin and paclitaxel, and is the drug's second approved indication in India without requiring PD-L1-based patient selection.
